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Critical Appraisal of Quality of Clinical Practice
Guidelines for Treatment of Psoriasis Vulgaris,
2006–2009
Jerry K.L. Tan1, Barat J. Wolfe2, Ranko Bulatovic3, Emily B. Jones3 and Andrea Y. Lo3
Numerous international clinical guidelines for management of psoriasis have recently been published. We
evaluated the quality of guidelines published between 2006 and December 2009 using the Appraisal of
Guidelines Research and Evaluation (AGREE) instrument. Eight guidelines from five separate working groups
fulfilled inclusion criteria and were evaluated. Four used the standards established by the AGREE instrument in
the process of development of their guidelines. Each of the guidelines uniformly received high domain scores
(i.e., 490%) for scope and purpose (range of 94–100%), and clarity and presentation (range of 92–100%).
Nevertheless, each of the eight guidelines had important shortcomings (item scores p2/4, in which 4 indicates
strongly agree and 1 indicates strongly disagree that specific items have been adequately addressed) in at least
one item including: stakeholder involvement (by lack of piloting and inadequate determination of patient
views), development rigor (inadequate procedure for updating), applicability (by lack of discussion on
organizational barriers), and editorial independence (from funding body). Despite the use of predefined
standards in their development, important deficiencies exist in the most recent clinical treatment guidelines for
psoriasis.
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INTRODUCTION
Clinical practice guidelines are systematically developed
recommendations for appropriate health care for specific
clinical circumstances. By reducing discrepancies between
scientific evidence and clinical practice, guidelines have the
potential to improve the quality of care delivered to patients
(Woolf et al., 1999; Davis et al., 2007). Translating
recommendations into practice and improved outcomes
requires physician adherence to guidelines. However, multi-
ple impediments to their implementation have been identi-
fied, including irreconcilability with patient preferences,
inadequate facilities or resources for their implementation,
guidelines complexity, and other physician-based factors
(Cabana et al., 1999). The latter include lack of awareness,
unfamiliarity, or disagreement with the guidelines; belief that
guideline recommendations cannot be implemented or that
desired outcomes will not be achieved; and lack of
motivation for changing practice. Many of these cognitive
concerns may be abrogated during the guideline development
processes by adopting methodologies to achieve appropriate
standards of quality. In particular, the process of development
should provide confidence that the potential for bias is
minimized and addressed as appropriate, and that the
recommendations are valid and feasible for clinical practice
(AGREE Collaboration, 2001). Some of these standards
include: ensuring that the clinical scope and purpose are
well defined and relevant; the process involves stakeholders
including professional groups and patients, and piloting the
guidelines to ensure practicability; developmental rigor based
on systematic search for medical evidence, subsequent
formulation of recommendations, and periodic updating;
clarity of recommendations and ease of access; and applic-
ability including consideration of organizational barriers and
cost implications. The credibility of guidelines is also
dependent on editorial transparency by autonomy and
independence from funding bodies and in declaration of
conflicts of interest by the developers.
These features represent the relevant domains in the
Appraisal of Guidelines Research and Evaluation (AGREE)
instrument, a framework of establishing the quality of clinical
guidelines (AGREE Collaboration, 2001; Vlayen et al., 2005).
AGREE was developed through a multistage approach (i.e.,
item generation, selection, and scaling process, field testing,
and refinement) involving extensive discussion with research-
ers from 13 countries (AGREE Collaboration, 2003). The
development of AGREE reflected a need for reference
standards and a means by which to assess the quality
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of clinical guidelines. The processes and circumstances
leading to the eventual development of AGREE are available
in greater detail in Lohr and Field (1992), Grol et al. (1998),
Lohr (1998) , and Cluzeau et al. (1999). The AGREE is one of
the few validated instruments that is used to assess
methodological quality of clinical guidelines, and is unique
among validated instruments in using a numerical scale
(Vlayen et al., 2005). It is a generic instrument suitable for the
spectrum of medical applications in diagnosis, health
promotion, treatment, and other interventions.
In psoriasis, AGREE has been applied to clinical guidelines
from the Netherlands, Britain, and Germany as a foundation
for the subsequent development of common European
guidelines (Nast et al., 2009). Concurrently, other national
and regional psoriasis guidelines have also recently been
published or updated, including those from Canada
(Canadian Psoriasis Guidelines Committee, 2009), the United
States (Gottlieb et al., 2008; Menter et al., 2008; Menter
et al., 2009a, b), Britain (Smith et al., 2009), and Europe
(Pathirana et al., 2009). The purpose of this study is to
appraise the methodological quality of current clinical
psoriasis guidelines and to highlight their strengths and
shortcomings in informing clinicians and psoriasis patients.
The AGREE instrument was chosen as the appraisal tool in
this study because of the following reasons: the precedent
established for evaluating psoriasis guidelines by Nast et al.
(2009); as one of only two validated tools and the sole
instrument using a numerical system; and finally, as an
important component of the recommendations of the
International Patient Decision Aid Standards in development
of patient decision aids, of which drafting information from
clinical guidelines is an important first step.
RESULTS
Our literature search uncovered 58 publications, of which
50 were excluded: 6 position papers, 4 editorials, 5
non-evidence-based recommendations, 11 systematic reviews,
19 primary research papers, and 5 focused on single
treatments. Accordingly, 8 publications met our inclusion
criteria. Of these, there were five sets of guidelines: one
Canadian (Canadian Psoriasis Guidelines Committee, 2009),
one German (Nast et al., 2007), one European (Pathirana
et al., 2009), one British (Smith et al., 2009), and four
separate articles from the same American Academy of
Dermatology working group (Gottlieb et al., 2008, Menter
et al., 2008, 2009a, b) (see Table 1). The latter published their
guidelines as separate monographs rather than as a single
entity. Although we refer to these as the ‘‘American
guidelines,’’ the four related publications have been app-
raised as separate documents and are presented separately in
the following sections and tables. Four of the five groups (i.e.,
Canadian, German, European, and British) used the AGREE
criteria as standards in their development process.
The Canadian guidelines were comprehensive and encom-
passed the spectrum of plaque psoriasis severity including
involvement at nails, scalp, inverse regions, and palms and
soles. Special populations were also considered: children,
pregnancy, the elderly, hepatitis, HIV, solid tumors, elective
surgery, and vaccination. Treatment options reviewed ex-
tended from topicals, phototherapy, conventional systemic,
biologics, and combinations thereof. Ustekinumab, the most
recently approved biologic agent for psoriasis in Canada, was
not reviewed. This guideline scored highly (X80% on all
domains but one) with only two items scoring p2. One item
was for inadequate information on procedures for updating
the guidelines (1.75), and the other item was for lack of
piloting (2), bringing the domain score for stakeholder
involvement to 79%.
The German guidelines were published in 2007 in both
complete and abbreviated versions. Only the complete
version was included in this appraisal to avoid duplication.
These guidelines were also comprehensive and considered
the spectrum of therapeutic options. Highest scores were
observed for rigor of development (100%) and clarity and
presentation (100%). Lowest scores were observed for
editorial independence from the funding body (1) and
piloting of the guidelines (1), resulting in scores o80% for
two domains: stakeholder involvement (75%) and editorial
independence (50%). Although individual conflicts of interest
were not reported in the guideline itself, they were made
available to readers at the guideline developers’ website
www.psoriasis-leitlinie.de.
The European guidelines specifically focused on photo-
therapy and systemic therapies for psoriasis. The complete
spectrum of phototherapy, registered oral agents, and
biologics (except for the more recently available agent,
ustekinumab) were reviewed. Highest domain scores were
observed for rigor of development (99%) and clarity and
presentation (100%). The lowest domain scores were
in editorial independence (63%) and applicability (78%)
because of low item scores for potential of inadequate
editorial independence from the funding body (1.75) and
insufficient discussion of organizational barriers (2), respec-
tively. In addition, the marginal domain score for stakeholder
involvement (81%) was due to a low item score of 2 for
piloting.
The British guidelines were focused solely on biologics,
namely infliximab, etanercept, adalimumab, and ustekinumab.
It was the sole guideline in this group that also included
ustekinumab. Highest domain scores were observed for
scope and purpose (100%), rigor of development (100%),
and clarity and presentation (100%). It scoredo80% on two
domains, including stakeholder involvement (77%) and
applicability (78%), and only a single item scored o3
(piloting score 1.25). Although funding for these guidelines
was not explicitly addressed, by referring back to the original
2005 manuscript (Smith et al., 2005), and the support
document for potential guidelines development of the British
Association of Dermatologists (Bell and Ormerod, 2009), our
reviewers were able to infer editorial independence.
Finally, four separate American guidelines have been
published by the same working group of the American
Academy of Dermatology. Two further guidelines from this
group are expected in the near future. Each publication
addresses a different aspect of psoriasis and psoriatic arthritis
management including: topicals, conventional systemics, and
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biologics. Among these four, highest domain scores were
observed for rigor of development (99% for all four) and
editorial independence (100% for all four). Lowest domain
scores were observed for stakeholder involvement (51%),
because of inadequacies in seeking patient views (2) and
piloting (2.13); and in applicability (53% for American
1, 61% for American 3, and 67% for American 4) because
of inadequate discussion of organizational barriers (1.5, 1,5,
and 2.75, respectively).
DISCUSSION
Clinical guidelines are an increasingly important component
of clinical practice (Woolf et al., 1999; Krahn and Naglie,
2008). They are viewed as a means of translating research
findings into clinically relevant information to support
physicians and patients in decision making (Davis et al.,
2007). The yield of current clinical psoriasis guidelines from
multiple dermatology associations underscores the perceived
value of these documents. We highlight the following
findings in this appraisal, undertaken to evaluate the quality
of these guidelines.
Four of the five sets of guidelines included in this analysis
were specifically developed in concordance with the AGREE
instrument. The American group applied evidence-based
methodology in accordance with the Administrative Regu-
lations for Clinical Guidelines of the American Academy
of Dermatology (available at http://www.aad.org/Forms/
Policies/Uploads/AR/AR%20Evidence-Based%20Clinical%
20Practice%20Guidelines.pdf). The latter involves six phases
capped off by a review process that is more extensive
than that required by the AGREE (American Academy of
Dermatology, 2009). However, although development of
clinical practice guidelines is referenced in this adminis-
trative document, there is a paucity of detail beyond
employment of evidence-based methodology. The American
guidelines scored lowest across the AGREE domains, likely
Table 1. Psoriasis guidelines reviewed
Group National society and authors Year Title Journal Scope
Canadian Canadian Psoriasis Guidelines
Committee
2009 Canadian guidelines for the
management of plaque
psoriasis, 1st edition
N/A Systemic agents
Biologics
Topical therapy
Phototherapy
Combination therapy
German Deutsche Dermatologische
Gesellschaft, Berufsverband
Deutsher Dermatologen
(Nast et al., 2007)
2007 Evidence-based (S3)
guidelines for the treatment of
psoriasis vulgaris
Journal of the German
Society of
Dermatology
Topical therapy
Phototherapy
Systemic agents
Climate therapy
Psychosocial therapy
European European Academy of
Dermatology and Venereology
(Pathirana et al., 2009)
2009 European S3-Guidelines on
the systemic treatment of
psoriasis vulgaris
Journal of the
European Academy of
Dermatology and
Venereology
Systemic agents (biologic and
non-biologic)
Phototherapy
British British Association of
Dermatologists
(Smith et al., 2009)
2009 British Association of
Dermatologists’ guidelines for
biologic interventions for
psoriasis 2009
British Journal of
Dermatology
Biologics
American American Academy of
Dermatology
(Menter et al., 2008)
2008 Guidelines of care for the
management of psoriasis and
psoriatic arthritis: Section 1.
Overview of psoriasis and
guidelines of care for the
treatment of psoriasis with
biologics
Journal of the
American Academy of
Dermatology
Biologics
American Academy of
Dermatology
(Gottlieb et al., 2008)
2008 Section 2. Psoriatic arthritis:
Overview and guidelines of
care for treatment with an
emphasis on biologics
Journal of the
American Academy of
Dermatology
Biologics
American Academy of
Dermatology
(Menter et al., 2009a)
2009 Section 3. Guidelines of care
for the management and
treatment of psoriasis with
topical therapies
Journal of the
American Academy of
Dermatology
Topical therapies
American Academy of
Dermatology
(Menter et al., 2009b)
2009 Section 4. Guidelines of care
for the management and
treatment of psoriasis with
traditional systemic agents
Journal of the
American Academy of
Dermatology
Systemic agents
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attributable to not using it explicitly during guideline
development. There would seem to be some inevitable
design-related bias in validating guidelines against the very
tool that was used to design them (i.e., using the AGREE to
assess guidelines that referenced this instrument in their
development). As we mentioned previously, our choice to
use the AGREE as the appraisal tool was based on its status as
one of the few validated tools available (and only validated
tool with a numerical scoring system), and previous use by
other psoriasis researchers. This paper also reflects the first
step (i.e., literature review and appraisal of content) by our
research team to create a decision aid for psoriasis patients.
The AGREE instrument is a tool supported by the Interna-
tional Patient Decision Aid Standards to translate evidence
from practice guidelines for use in decision aids (Elwyn et al.,
2006). In addition, although the majority of recent psoriasis
guidelines working groups have referenced the AGREE tool
during development, establishing prespecified quality criteria
during the development process does not ensure the
congruence of the final product with these criteria—as
reflected in the lower scores across several domains.
Importantly, the instrument does have inherent weak-
nesses. There is subjectivity in scoring of component items as
there are no objective metrics by which to rate specific items
(e.g., organizational barriers, cost implications, and side
effects). Although a numerical scoring system is in place,
there are no instructions regarding what each score reflects,
and how this information should be used in forming
recommendations about the guidelines. In addition, it does
not allow subjective classification of overall guideline quality
(excellent, good, or poor) nor assessment of the content nor
quality of evidence provided in making recommendations
(Vlayen et al., 2005). Furthermore, it cannot capture the
guideline development processes beyond the scope of the
final guideline document (Quaseem et al., 2007). In 2003, a
review of the quality of North American guidelines from
various disciplines revealed that their methodological quality
had decreased over the preceding decade (Hasenfeld and
Shekelle, 2003). They suggested that having a singular
instrument for appraising guidelines would also be beneficial
in their development process, and that AGREE would be the
closest to such an international standard.
Each of the guidelines reviewed was clearly developed
with physicians as the target audience. However, as the
purpose of clinical guidelines is to ‘‘assist practitioner and
patient decisions’’ (emphasis added, Field and Lohr, 1990,
p. 527), they should also be developed with patients as a
potential audience. Unfortunately, guideline developers
generally do not adequately consider patient preferences
(Krahn and Naglie, 2008), which can result in discordance
between best practice based on the guidelines, and that
based on individual patient needs (see, e.g., Protheroe et al.,
2000). Furthermore, we note that although efficacy data were
widely addressed in these guidelines, there was a notable
paucity of information on risks. In their absence, the
risk–benefit profiles of proffered treatments are incalculable,
and the process of treatment selection seemingly based on
efficacy alone. If the point of guidelines is to offer
recommendations to improve clinical decisions, the quality
of content may be as important as the quality of the
methodology used in development. Although this concept
is beyond the scope of this paper, this has been addressed by
the AGREE team using qualitative analysis (see Burgers et al.,
2002). Similar methodology may be applied in future
research to address this question for psoriasis.
The current guidelines generally received the lowest
domain scores across the board on stakeholder development
(i.e., no group scoring 100%), largely because of the lack of
piloting the guidelines, and lack of patient perspectives
(American guidelines). In addition, lower scores were
observed in applicability, the only other domain to not
receive a 100% rating by at least one team. In the absence of
specific AGREE instructions upon which to identify a ‘‘poor’’
score, we attempted to numerically represent these values by
identifying items scoring o2/4 as reflecting important short-
comings. According to AGREE, scores of 2 and 1 represent
a reviewer disagreeing or strongly disagreeing, respectively,
that an item has been adequately addressed (AGREE
Collaboration, 2001). On the basis of the domain scores
alone, the true shortcomings of the guidelines may not be
obvious as most of the scores are 480%. However,
evaluating the scores for each individual item, and addition-
ally considering the relevance of lower scored items, can
help to highlight deficiencies.
The relevance of the various AGREE domains will vary
with stakeholder perspective, as patients, dermatologists,
regulatory authorities, and drug payers may have very
different concerns related to psoriasis management. Because the
AGREE instrument is a tool to appraise the methodological
quality of guidelines, it was anticipated that domains
related to developmental rigor and presentation would score
highly. However, it may well be that applicability issues,
which were among the lowest scores, represent the more
critical issues to physicians and health policy makers as they
speak directly to the implementation of guidelines. Organi-
zational barriers and cost implications require greater
attention in these guidelines to ensure that treatment
recommendations are congruent with locoregional resources
as well as patient needs. Although one explicit objective of
clinical guidelines is to minimize discrepancy between what
is scientifically supported and what is actually practiced
by clinicians, the lack of attention to issues of applicability
in these guidelines are inconsistent with this goal.
In summary, despite rigorous methodologies used in the
development of current psoriasis guidelines, we identified
systematic deficiencies in stakeholder involvement and in
their applicability. Although the overall methodological
quality of the guidelines was high, these deficiencies may
undermine the feasibility and implementation of their
recommendations in clinical practice.
MATERIALS AND METHODS
A systematic literature search was performed to identify evidence-
based English language clinical practice guidelines for psoriasis
vulgaris. We used four computerized databases (i.e., PubMed,
MEDLINE, EBM, and National Guidelines Clearinghouse) with the
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Table 2. Mean AGREE item scores and domain scores1
Domain and item Canadian German European British American 1 American 2 American 3 American 4
Scope and purpose
Overall objectives described 4 4 4 4 4 4 4 4
Clinical questions described 4 3.75 3.75 4 4 3.5 3.5 3.5
Patients described 4 4 4 4 4 4 4 4
Domain score 100% 97% 97% 100% 100% 94% 94% 94%
Stakeholder involvement
Relevant professional groups included 3.5 4 4 4 3.25 3.25 3.25 3.25
Patient views sought 4 4 3.75 4 2 2 2 2
Target users defined 4 4 4 4 2.75 2.75 2.75 2.75
Guideline piloted 2 1 2 1.25 2.13 2.13 2.13 2.13
Domain score 79% 75% 81% 77% 51% 51% 51% 51%
Rigor of development
Systematic literature search 4 4 4 4 4 4 4 4
Selection criteria described 4 4 4 4 4 4 4 4
Method of formulating recommendations
described
4 4 4 4 4 4 4 4
Benefits, side effects, risks considered in
recommendations
4 4 4 4 4 4 4 4
Link between recommendations and evidence 4 4 4 4 4 4 4 4
External review before publication 4 4 4 4 3.75 3.75 3.75 3.75
Procedure for updating provided 1.75 4 3.75 4 4 4 4 4
Domain score 89% 100% 99% 100% 99% 99% 99% 99%
Clarity and presentation
Recommendations specific and unambiguous 4 4 4 4 4 4 4 4
Different treatment options clearly presented 4 4 4 4 4 4 4 4
Recommendations clearly identifiable 4 4 4 4 4 3.75 4 4
Tools for application provided 3.5 4 4 4 3.75 3.75 3.5 3
Domain score 96% 100% 100% 100% 98% 96% 96% 92%
Applicability
Organizational barriers discussed 4 3 2 3 1.5 2.75 1.5 2
Cost implications considered 3 4 4 3 2.25 4 3 3
Key review criteria included 3.25 4 4 4 4 4 4 4
Domain score 81% 89% 78% 78% 53% 86% 61% 67%
Editorial independence
Editorial independence from funding body 4 1 1.75 3 4 4 4 4
Conflicts of interest reported 4 4 4 4 4 4 4 4
Domain score 100% 50% 63% 83% 100% 100% 100% 100%
AGREE, Appraisal of Guidelines Research and Evaluation.
1Domain score calculated based on standardized score and not mean item scores.
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keywords ‘‘psoriasis,’’ ‘‘treatment,’’ and ‘‘guideline’’ and publication
between 2006 and December 2009 as search criteria. Excluded
were double-hits, position papers, editorials, non-evidence-based
recommendations, systematic reviews, other primary research, and
publications focused on single treatments.
Four reviewers (BW, RB, EJ, and AL) independently evaluated
each guideline using the AGREE instrument (AGREE Collaboration,
2001). The latter comprised 23 items in 6 domains: 3 for scope and
purpose, 4 for stakeholder involvement, 7 for rigor of development,
4 for clarity and presentation, 3 for applicability, and 2 for editorial
independence. Each item is rated on a scale of 1–4 (with 1
representing ‘‘strongly disagree’’ and 4 representing ‘‘strongly
agree’’) with higher scores reflecting higher quality. Scores reflecting
inadequate quality were established as p2. None of the current
reviewers had been involved in development of the guidelines and
there were no conflicts of interest applicable to the review process.
Although this study was partially funded by the Canadian
Dermatology Foundation, this is a wholly separate and independent
entity from the Canadian Guidelines Committee of the Canadian
Dermatology Association.
The appraisal process was first piloted with the Canadian
Diabetes Guidelines (Canadian Diabetes Association Clinical
Practice Guidelines Expert Committee, 2008) to ensure clarity.
Although not inherently part of AGREE instructions, the piloting
process revealed a necessity for additional discussion of disparate
scores by reviewers, followed by a second round of independent
scoring and calculation of domain scores. This was done to
reduce the potential of overlooking relevant information in
long documents, and because of the subjective nature of allocating
scores with AGREE. Accordingly, after independent review,
discrepancies in ratings were addressed by group meeting, discus-
sion, and repeat independent scoring. Of the 184 total
items reviewed (i.e., 22 items for 8 guidelines), there were only
19 items in which reviewers did not achieve full concordance
after repeat scoring. Standardized domain scores were calculated as
per AGREE scoring instructions (AGREE Collaboration, 2001) by
summing up all the scores of the individual items in each domain
and standardizing the total as a percentage of the maximum score for
that domain. Table 2 shows the item scores of each guideline
(averaged across the four reviewers), and the final standardized
domain scores.
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